CEO Malcolm McColl speaks at Bell Potter Healthcare Conference
ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at the Bell Potter Healthcare Conference 2023 held in November is available to view here.
ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites. Intralesional administration well tolerated, no dose-limiting toxicities. Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]
ImmVirX reports on operations for FY23
Melbourne, Australia 21 September 2023 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next wave of receptor-targeted oncolytic viral immunotherapies for patients confronted with common yet formidable cancers, presents a summary of its operations for the financial year ending 30 June 2023. The year was headlined by the progress of IVX037, ImmVirX’s […]
ImmVirX raising $25m led by renowned healthcare VC OneVentures
– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]
ImmVirX enters the clinic with next generation oncolytic virus
First patient on trial in colorectal, gastric and ovarian cancer study (CP-IVX001) Melbourne, Australia 11 April 2023 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that the first patient […]
ImmVirX receives $2.81M R&D tax refund for FY22
ImmVirX receives $2.81M R&D tax refund for FY22 Melbourne, Australia 28 November 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $2,813,837 Research and Development (R&D) tax refund […]
ImmVirX reports on operations for FY22
Melbourne, Australia 26 September 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to report on its operations for the year ending 30 June 2022. The year has seen […]
ImmVirX receives $858,183 R&D tax refund
Melbourne, Australia 4 March 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that it has received a $858,183 Research and Development (R&D) tax refund as part of the […]
ImmVirX extends Research Services Agreement with University of Newcastle & HMRI through to 2024
Melbourne, Australia 6 December 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the option to extend its relationship with the University of Newcastle through to December 2024. Under the ongoing Research Services […]
ImmVirX closes upsized $25m Series A financing
Melbourne, Australia 8 November 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the successful upsizing and completion of its $25m Series A financing. The initial tranche of $22m […]
